Speakers: Frank Wild, Christian Jacke
The drug related consumption and expenses continue to increase every year. This is particularly true for private insurances (PKV) which reimburse pharmaceutical innovations. In comparison to the compulsory sickness insurance, only a small number of regulations allow to reduce prices. This PKV characteristic may be beneficial for the assured person and the physician because therapy planning and personalized drug selection occurs independently from budget restraints. However, medical treatment of high quality is challenged especially in the case of chronical diseases. The aim of study is to estimate drug related expenses by age and sex for the present and the future.